Tumor angiogenesis.

Cancer genome landscapes. Science (2013) 25.33

The molecular biology of head and neck cancer. Nat Rev Cancer (2010) 9.84

Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer (2009) 9.26

Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell (2008) 4.51

Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol (2009) 4.17

Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer (2010) 3.48

Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44

The therapeutic promise of the cancer stem cell concept. J Clin Invest (2010) 3.26

A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature (2011) 3.25

Differential macrophage programming in the tumor microenvironment. Trends Immunol (2012) 3.18

Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol (2009) 3.02

Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol (2010) 3.02

VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer (2008) 3.02

Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol (2009) 2.97

Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer (2010) 2.93

Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. Sci Transl Med (2014) 2.69

G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A (2009) 2.68

P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci U S A (2010) 2.49

The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol (2008) 2.46

Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol (2009) 2.41

Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol (2009) 2.29

Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res (2009) 2.23

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis (2009) 2.15

Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. Nat Rev Drug Discov (2010) 2.14

Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer (2008) 2.10

Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys (2009) 2.07

Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis (2014) 2.07

Tumor metabolism: cancer cells give and take lactate. J Clin Invest (2008) 1.97

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol (2009) 1.95

Role of pancreatic stellate cells in pancreatic cancer metastasis. Am J Pathol (2010) 1.87

Endothelial epsin deficiency decreases tumor growth by enhancing VEGF signaling. J Clin Invest (2012) 1.87

Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model. Proc Natl Acad Sci U S A (2009) 1.81

Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer Res (2010) 1.80

Chemokines as mediators of neovascularization. Arterioscler Thromb Vasc Biol (2008) 1.71

Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J Biol Chem (2009) 1.68

Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. Blood (2011) 1.66

Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol (2012) 1.65

Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment. Clin Cancer Res (2010) 1.64

Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov (2012) 1.61

A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med (2009) 1.59

MicroRNAs: opening a new vein in angiogenesis research. Sci Signal (2009) 1.58

Evolutionarily repurposed networks reveal the well-known antifungal drug thiabendazole to be a novel vascular disrupting agent. PLoS Biol (2012) 1.58

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. Nat Med (2016) 1.55

Spheroid-based human endothelial cell microvessel formation in vivo. Nat Protoc (2009) 1.55

Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim Biophys Acta (2009) 1.54

Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer (2010) 1.54

Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett (2008) 1.53

Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS One (2012) 1.53

Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest (2011) 1.52

VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ (2009) 1.52

PLD1-dependent PKCgamma activation downstream to Src is essential for the development of pathologic retinal neovascularization. Blood (2010) 1.46

Coup d'Etat: an orphan takes control. Endocr Rev (2011) 1.45

Bench-to-bedside review: Angiopoietin signalling in critical illness - a future target? Crit Care (2009) 1.45

VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. J Exp Med (2010) 1.45

Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal (2013) 1.45

Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model. ASN Neuro (2011) 1.44

CXC chemokines in cancer angiogenesis and metastases. Adv Cancer Res (2010) 1.44

COUP-TFII regulates tumor growth and metastasis by modulating tumor angiogenesis. Proc Natl Acad Sci U S A (2010) 1.43

Insufficient radiofrequency ablation promotes angiogenesis of residual hepatocellular carcinoma via HIF-1α/VEGFA. PLoS One (2012) 1.42

The Vital Role of Blood Flow-Induced Proliferation and Migration in Capillary Network Formation in a Multiscale Model of Angiogenesis. PLoS One (2015) 1.41

Rhinitis and epistaxis in patients treated by anti-angiogenic therapy. Invest New Drugs (2008) 1.39

Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature. Cancer Cell (2017) 1.39

Axl is essential for VEGF-A-dependent activation of PI3K/Akt. EMBO J (2012) 1.38

Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol (2012) 1.37

TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types. Cancer Cell (2012) 1.34

PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nat Med (2011) 1.33

How platelets safeguard vascular integrity. J Thromb Haemost (2011) 1.32

Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited. Acta Neuropathol (2012) 1.30

The complexities of obesity and diabetes with the development and progression of pancreatic cancer. Biochim Biophys Acta (2010) 1.29

Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic polyA activation. Mol Cell (2011) 1.28

Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. J Oncol (2010) 1.28

Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol (2010) 1.27

Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res (2013) 1.27

Host-derived tumor endothelial marker 8 promotes the growth of melanoma. Cancer Res (2009) 1.27

Synergistic actions of hematopoietic and mesenchymal stem/progenitor cells in vascularizing bioengineered tissues. PLoS One (2008) 1.26

Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs (2010) 1.25

Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat glioma. PLoS One (2010) 1.24

Oxygen-controlled three-dimensional cultures to analyze tumor angiogenesis. Tissue Eng Part A (2010) 1.24

Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med (2014) 1.24

Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. Mol Endocrinol (2010) 1.24

Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer. Cancer Res (2012) 1.23

Angiogenesis as a therapeutic target in malignant gliomas. Oncologist (2009) 1.23

The tumor microenvironment in colorectal carcinogenesis. Cancer Microenviron (2010) 1.23

Microfluidic culture models of tumor angiogenesis. Tissue Eng Part A (2010) 1.23

Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARα mediated mechanism. PLoS One (2011) 1.22

Application of polychromatic flow cytometry to identify novel subsets of circulating cells with angiogenic potential. Cytometry A (2010) 1.22

Molecular diversity of VEGF-A as a regulator of its biological activity. Microcirculation (2009) 1.22

CXCR4/YY1 inhibition impairs VEGF network and angiogenesis during malignancy. Proc Natl Acad Sci U S A (2010) 1.21

The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. Mol Oncol (2012) 1.21

Hedgehog promotes neovascularization in pancreatic cancers by regulating Ang-1 and IGF-1 expression in bone-marrow derived pro-angiogenic cells. PLoS One (2010) 1.21

Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist Updat (2009) 1.20

The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review. PLoS One (2013) 1.20

Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med (2012) 1.20

Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc Natl Acad Sci U S A (2009) 1.19

The role IL-1 in tumor-mediated angiogenesis. Front Physiol (2014) 1.19

Genome-wide association study of age-related macular degeneration identifies associated variants in the TNXB-FKBPL-NOTCH4 region of chromosome 6p21.3. Hum Mol Genet (2012) 1.18

Emerging treatments for choroidal metastases. Surv Ophthalmol (2011) 1.18

Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways. Cancer Res (2009) 1.18

The evolutionarily conserved TSC/Rheb pathway activates Notch in tuberous sclerosis complex and Drosophila external sensory organ development. J Clin Invest (2009) 1.17

Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer. Dose Response (2010) 1.16

Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02

Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52

Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94

Isolation of putative progenitor endothelial cells for angiogenesis. Science (1997) 30.27

Targeting HIF-1 for cancer therapy. Nat Rev Cancer (2003) 28.01

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 23.44

A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 21.59

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (1996) 18.47

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature (1996) 16.92

A perivascular niche for brain tumor stem cells. Cancer Cell (2007) 11.55

Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov (2007) 11.46

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol (2004) 10.55

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov (2004) 9.96

VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell (2006) 9.32

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell (2005) 9.18

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 9.05

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest (2003) 8.34

Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell (2005) 7.90

Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science (2003) 7.86

Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell (2004) 7.61

Autocrine VEGF signaling is required for vascular homeostasis. Cell (2007) 7.37

Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol (2006) 7.19

Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature (2006) 7.01

Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res (2006) 6.77

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 6.76

Clinical translation of angiogenesis inhibitors. Nat Rev Cancer (2002) 6.58

Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature (2006) 6.56

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res (2000) 6.42

The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer (2004) 6.32

Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest (1999) 6.32

Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest (2006) 6.12

VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer (2002) 5.96

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest (2000) 5.52

Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med (2006) 5.22

Tumor induction of VEGF promoter activity in stromal cells. Cell (1998) 5.20

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell (2007) 5.09

Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science (2006) 4.79

Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science (2008) 4.71

Signaling vascular morphogenesis and maintenance. Science (1997) 4.55

The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer (2006) 4.55

Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A (2006) 4.51

Effect of p53 status on tumor response to antiangiogenic therapy. Science (2002) 4.41

Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res (2005) 4.38

Disrupting tumour blood vessels. Nat Rev Cancer (2005) 4.35

Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov (2007) 4.27

Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci U S A (2007) 4.27

Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell (2007) 4.11

VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature (2002) 4.10

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A (2007) 4.08

Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci U S A (2004) 4.06

Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol (2005) 3.83

Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell (2005) 3.74

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol (2008) 3.71

Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature (2007) 3.70

Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res (2007) 3.49

Genes that distinguish physiological and pathological angiogenesis. Cancer Cell (2007) 3.35

Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem (2005) 3.30

The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol (2007) 3.25

Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med (2005) 3.19

Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res (2003) 3.09

The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer (2007) 2.96

Endogenous inhibitors of angiogenesis. Cancer Res (2005) 2.88

Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science (2006) 2.78

Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood (2007) 2.74

Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell (2004) 2.71

Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer (2007) 2.68

Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev (2007) 2.60

Vascular-targeting therapies for treatment of malignant disease. Cancer (2004) 2.54

Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med (2007) 2.37

Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res (2007) 2.35

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer (2006) 2.33

The role of neuropilins in cancer. Mol Cancer Ther (2006) 2.28

Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest (2007) 2.28

Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer (2006) 2.27

VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A (2007) 2.19

G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells. Biochem Biophys Res Commun (2002) 2.13

Vascular leukocytes contribute to tumor vascularization. Blood (2004) 2.03

Chemokines direct endothelial progenitors into tumor neovessels. Proc Natl Acad Sci U S A (2005) 1.97

A cancer drug shows promise, at a price that many can't pay. N Y Times Web (2006) 1.97

Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Invest (2004) 1.90

Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin Cancer Res (2004) 1.87

The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era. Ann Oncol (2003) 1.83

Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood (2005) 1.80

Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res (2004) 1.77

Granulocyte colony-stimulating factor promotes tumor angiogenesis via increasing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer animal models. Int Immunol (2005) 1.75

Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood (2006) 1.69

Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer (2007) 1.61

Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer (2006) 1.59

Cancer research. Mutant stem cells may seed cancer. Science (2003) 1.50

Targeting endothelial and tumor cells with semaphorins. Cancer Metastasis Rev (2007) 1.34

Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resist Updat (2004) 1.34

How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy. Cancer Biol Ther (2005) 1.29

Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells. Cancer Metastasis Rev (2007) 1.23

Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis? Trends Mol Med (2007) 1.10

Angiogenesis and antiangiogenic therapy in hematologic malignancies. Crit Rev Oncol Hematol (2006) 1.09

Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies. Curr Drug Targets (2007) 1.07

Blockade of the vascular endothelial growth factor-receptor 2 pathway inhibits the growth of human renal cell carcinoma, RBM1-IT4, in the kidney but not in the bone of nude mice. Int J Oncol (2007) 0.87